November 15, 2017
2 min watch

VIDEO: Significant improvements for skin disease activity seen in patients with dermatomyositis treated with anabasum

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

SAN DIEGO — At the American College of Rheumatology Annual Meeting, Victoria P. Werth, MD, spoke about a study that evaluated the safety and efficacy of anabasum (JBT-101, Corbus Pharmaceuticals) in patients with dermatomyositis. She said patients treated with anabasum saw significant improvements for measures of skin disease activity.